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Purpose: Evening administration of the conven-
tional immediate-release (IR) formulation of simvas-
tatin is recommended because of its short half-life (1.9
hours). In a healthy population, morning administra-
tion of a controlled-release (CR) formulation of
simvastatin was shown to have equivalent lipid-
lowering efﬁcacy and a safety proﬁle similar to that
of evening doses of IR simvastatin. The present study
aimed to verify noninferiority and to compare the
safety of morning administration of CR simvastatin
with that of evening administration of IR simvastatin
in patients with chronic kidney disease (CKD) who
have dyslipidemia.
Methods: The present study was a prospective,
multicenter, double-blind, Phase IV trial with an
active comparator. We randomly assigned 122 pa-
tients with CKD and dyslipidemia to 1 of 2 drug
administration groups: morning administration of CR
simvastatin 20 mg (test group) and evening admin-
istration of IR simvastatin 20 mg (control group).
After 8 weeks, the treatment outcomes and adverse
effects of the 2 treatments were compared.
Findings: The mean (SD) percentage of change in
serum LDL-C at the end of treatment was –35.1%
(15.7%) for the test group and –35.6% (14.6%) for
the control group. The difference between the 2
groups was not signiﬁcant (P ¼ 0.858). The 95% CI1182of the difference in the percentage of change of LDL-C
between the test and control groups was –6.0 to 5.0.
There was no difference in the percentage of change of
total cholesterol (–24.3% [12.5%] vs –26.5%
[12.0%], P ¼ 0.317), triglyceride (–10.6% [35.1%]
vs –12.4% [33.2%], P ¼ 0.575) and HDL-C (10.2%
[20.7%] vs 4.5% [11.4%], P ¼ 0.064). Treatment-
related adverse events were similar in both groups (10
events in the test group vs 8 events in the control
group, P ¼ 0.691).
Implications: The efﬁcacy of morning administra-
tion of CR simvastatin was noninferior to evening
administration of IR simvastatin in patients with
CKD. Furthermore, the safety proﬁle analysis showed
no signiﬁcant difference between the 2 treatments.
Morning administration of CR simvastatin is expected
to increase patient compliance and therefore better
control of dyslipidemia in CKD patients. (Clin Ther.
2014;36:1182–1190) & 2014 The Authors. Published
by Elsevier HS Journals, Inc.Volume 36 Number 8
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release preparations, drug administration schedule,
dyslipidemia, simvastatin.INTRODUCTION
3-Hydroxy 3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors, also known as statins, are
a highly potent group of agents that reduce serum
LDL-C levels. Previous clinical trials have reported
that statin therapy is beneﬁcial for the primary1 and
secondary2–4 prevention of cardiovascular disease,
such as coronary atherosclerosis. Statin therapy is of
particular beneﬁt to dyslipidemia patients with
chronic kidney disease (CKD), which is associated
with a high incidence and increased severity of
cardiovascular disease.5 The Kidney Disease Out-
come Quality Initiative guidelines for dyslipidemia6
recommend that lipid-lowering therapy, along with
therapeutic lifestyle modiﬁcation, should be initiated
for CKD patients with LDL-C levels above 100 mg/
dL. According to the latest meta-analysis of statin
therapy in CKD, all-cause and cardiovascular mortal-
ity was signiﬁcantly decreased without increasing
treatment-related adverse effects.7,8
Despite the beneﬁcial effects of statin therapy,
patients with chronic diseases who are taking medi-
cations in multiple doses are frequently noncompliant
in taking their medication.9–11 There is a diurnal
variation of plasma LDL-C levels, with the lowest
levels detected in the morning and the highest levels
peaked in the evening.12 Simvastatin is an established
HMG-CoA reductase inhibitor that has been clinically
evaluated in thousands of cases.2,13 In some trials
comparing the efﬁcacy of morning and evening ad-
ministration of simvastatin, there was signiﬁcantly
lower reduction in LDL-C levels when simvastatin
was given in the morning.14 However, taking simvas-
tatin in the evening may increase the complexity of the
dosing regimen, in turn, reducing patient compliance.9
Recently, a controlled-release (CR) simvastatin
formulation was released (Simvast CR tablet*); it
has a longer half-life (11.4 hours) than that of the
conventional immediate-release (IR) formulation (1.9
hours). In a Phase III trial of CR simvastatin, the
formulation was reported to have equivalent efﬁcacy*Trademark: Simvast CR tablets, Hanmi Pharmaceutical Co,
Ltd, Seoul, Republic of Korea.
August 2014and a similar safety proﬁle within the study popula-
tion as those of IR simvastatin.15 We designed a Phase
IV, postmarketing trial of CR simvastatin in CKD
patients. The purposes of the present study were
twofold: (1) to verify in CKD patients whether the
efﬁcacy of CR simvastatin administered in the
morning was noninferior to that of IR simvastatin
administered in the evening and (2) to assess whether
a regular dose regimen of CR simvastatin was safe
compared with that of IR simvastatin in CKD
patients.
METHODS
The present study was a prospective, randomized,
double-dummy, double-blind,, multicenter Phase IV
trial that evaluated the efﬁcacy and safety proﬁle of
morning administration of CR simvastatin tablets
compared with evening administration of IR simvas-
tatin tablets (Zocor tablet†) in CKD patients. The
participants were recruited from the following
hospitals in South Korea: Seoul National University
Hospital, Gachon University Gil Medical Center,
Seoul Eulji General Hospital, Hallym University
Sacred Heart Hospital, Inje University Ilsan Paik
Hospital, Hanyang University Seoul Hospital, and
Korea University Anam Hospital. Before entering the
study, all patients provided written informed consent.
The institutional review boards of each hospital
approved the study design, and the study was
performed in accordance with the Declaration of
Helsinki and its amendments.
Patients
The study was conducted from December 2010 to
May 2012. Patients, 20 to 75 years of age, with CKD
stage 3, 4, or 5 (predialysis) were enrolled if their
serum LDL-C levels were between 100 and 220 mg/dL
and their serum triglyceride (TG) levels were o400
mg/dL. The reasons for exclusion of patients were as
follows: previous hypersensitivity to components of
any HMG-CoA reductase inhibitor, drug abuse and
alcohol consumption of least 14 standard units per
week,16,17 impaired liver function (serum aspartate
aminotransferase or alanine aminotransferase level of
42 times the upper limit of normal), uncontrolled
diabetes (HgA1c level of 49.0%), uncontrolled†Trademark: Zocors tablet, Merck & Co, Inc, Whitehouse
Station, New Jersey.
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Clinical Therapeuticshypertension (systolic blood pressure 4160 mm Hg
or diastolic 4100 mm Hg at screening), congestive
heart failure with symptoms of New York Heart
Association Functional Class III or IV symptoms,
unstable angina, myocardial infarction, history of
percutaneous coronary intervention or bypass surgery,
cerebral infarction or transient ischemic accident and
deep venous thrombosis in the past 6 months, active
peptic ulcer disease, gastrointestinal disease that might
inﬂuence the absorption of the test drug, current
therapy with an immunosuppressant, and malignancy.
The following drugs were prohibited during the entire
study period: other
HMG-CoA reductase inhibitors, nicotinic acid de-
rivatives, omega-3 fatty acid
formulations, ﬁbric acids, peroxisome proliferator-
activated receptor γ agents, and bile acid sequestrants.
Screening and Treatment Period
At visit 1, all screened patients were instructed to
discontinue lipid-lowering medication during the
screening period and to initiate therapeutic lifestyle
changes (TLCs), including diet modiﬁcation, for 4
weeks. Participants’ serum lipid levels were reassessed
after 4 weeks of TLCs (visit 2). At visit 2, patients who
met the above LDL-C and TG criteria were randomly
assigned to 2 drug administration groups: CR simvas-
tatin (test group) and IR simvastatin (control group).
We used a ﬁxed-allocation (1:1) block-randomization
method. The size of each block was 4 patients. The
study referral institutions completed the random
assignment of patients. All clinicians and patients
remained blinded until the end of the study.
During 8 weeks of treatment, patients in the test
group took a CR formulation of simvastatin as a 20-
mg tablet in the morning and a placebo of IR
simvastatin in the evening. Conversely, patients in the
control group took a placebo of CR simvastatin in
the morning and an IR simvastatin 20-mg tablet in the
evening. Each placebo was prepared in the same color
and shape as the corresponding drugs so that patients
and physicians could not differentiate them (double-
blinding). Four weeks after randomization (visit 3), the
participants were contacted by telephone to check for
any adverse events or concomitant medications. If any
adverse events were reported, the participants were
asked to return to the outpatient clinic for an evalua-
tion. At 8 weeks (visit 4), the patients were evaluated
for drug compliance, efﬁcacy, and safety proﬁle1184pertaining to the treatment. Patients who dropped out
after randomization (1 subject in the test group and 2
in the control group) were also encouraged to visit for
the ﬁnal (efﬁcacy) laboratory tests at visit 4.Efficacy and Safety Profile Assessment
LDL-C, HDL-C, total cholesterol (TC), and TG
levels in 12-hour fasting blood samples were deter-
mined at week 0 (baseline) and week 8 (Wako Pure
Chemical Industries Ltd, Osaka, Japan). The primary
end point of the study was the percentage of change in
LDL-C levels over the 8 weeks of treatment. The
secondary end points were the percentage of change in
TC, HDL-C, and TG levels. For the safety proﬁle
assessment, vital signs and laboratory parameters
were monitored, including hemoglobin level; hema-
tocrit, white blood cell, and platelet counts; trans-
aminase, γ-glutamyl transferase, serum creatinine,
blood glucose, and creatine kinase levels; urinalysis;
and ECG.Statistical Analysis
The aim of the study was to conduct a noninfer-
iority comparison between a morning dose of CR
simvastatin and an evening dose of IR simvastatin.18
The margin of difference for noninferiority was
regarded as o–6.5%, according to previous
studies.19,20 When setting the statistical power at
80% and the α value at 0.05, the calculated number
of enrolled patients required was 52 in each group. An
assumed a dropout rate of 15% gave a ﬁnal sample
size of 61 patients in each group. The equation for
sample size determination was as follows:
n ¼ 2ðZα þ ZβÞ2σ2
ððμT  μCÞ  dÞ2
Zα = the limit value of α error (0.05) in normal
distribution, Zβ = the limit value of β error (0.20) in
normal distribution, d = noninferiority margin (6.5%),
and σ ¼ SD.
The primary and secondary end-point analyses
were based on the intention-to-treat (ITT) population,
which included any enrolled patients who took at least
1 dose of the medication and underwent efﬁcacy
testing at week 8. The safety proﬁle analysis was
based on the safety set, which was deﬁned as the
group of patients who had taken at least 1 tablet of
the study drug.Volume 36 Number 8
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levels, the primary end point, the Student t test was
performed to calculate the 95% CI of the percentage
of difference between the test and control groups. If
the 95% CI did not exceed the set point of the
noninferiority margin (–6.5%), the efﬁcacy of CR
simvastatin was considered to be noninferior. To
assess the signiﬁcance of the change in LDL-C, TC,
HDL-C, and TG levels before and after treatment, the
paired t test (to compare within groups) and Student t
test (to compare between groups) were used. In an
analysis of participant demography, continuous vari-
ables that followed a normal distribution were pre-
sented as mean (SD) and were analyzed using the
Student t test; categorical values were represented by
number and percentage and were analyzed by the χ2
or Fisher exact test. P o 0.05 was deﬁned as statisti-
cally signiﬁcant. All statistical analyses were performed
using SPSS 19.0 (SPSS Inc, an IBM company, Chicago,
Illinois).
RESULTS
A total of 122 patients were randomly assigned to
either the test (n = 62) or control (n = 60) group. OnScreening : Patients with dyslipid
12 rejected
TLC
122 subjects ran
118 patients at week 0
Discontinued administration : 1
Drug compliance < 75% : 4
Violate prohibited drug : 7
Others : 2
At week
PP popualtion
45 completed study
59 received morning administration
of CR simvastatin
1 refused after
randomization
Figure 1. Flow chart of the study. CKD ¼ chronic kidne
release; ITT ¼ intention-to-treat; PP ¼ per-pr
August 2014completion, 118 patients (59 for each group) were
included in the ITT population, after exclusion of 1
subject in the control group who refused to participate
immediately after enrollment without taking the study
drug and 3 in the test group who failed to undergo the
efﬁcacy evaluation blood test after 8 weeks of medi-
cation. Forty-ﬁve patients in the test group and 47 in
the control group completed the study (Figure 1).
Baseline Characteristics
Of the 118 patients assigned to treatment, 92
completed the 8-week trial. With regard to age, sex,
weight, CKD stage, alcohol consumption, underlying
disease, previous medication (including statins, aspirin,
angiotensin-converting enzyme inhibitors/angiotensin re-
ceptor blockers, β-blockers, calcium channel blockers,
and loop and thiazide diuretics), and baseline laboratory
test results (TC, TG, LDL-C, HDL-C, and creatinine
levels), there were no statistically signiﬁcant differences
between the test and control groups (Table I).
Changes in the Lipid Profile
Both the morning dose of CR simvastatin and
evening dose of IR simvastatin signiﬁcantly loweredemia and CKD (n = 168)
domized
 : ITT population
Discontinued administration : 2
Drug compliance < 75% : 4
Violate prohibited drug : 5
Others : 1
 8
 (N=92)
47 completed study
59 received evening administration
of IR simvastatin
3 failed to perform efficacy test
34 were in exclusion criteria
y disease; CR ¼ controlled-release; IR ¼ immediate-
otocol; TLC ¼ therapeutic lifestyle change.
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Table I. Baseline characteristics of the intention-to-treatment population in the trial.
Characteristic
Test Group
(n ¼ 59)
Control Group
(n ¼ 59)
Total
(N ¼ 118) P
Age, y, mean (SD) 56.9 (10.5) 57.0 (12.1) 57.0 (11.3) 0.978
Sex, male, no. (%) 28 (47.5) 29 (55.1) 57 (48.3) 0.853
Weight, kg, mean (SD) 64.3 (11.1) 63.7 (10.4) 64.0 (10.8) 0.764
CKD stage, no. (%) 0.827
3 43 (72.9) 40 (67.8) 83 (70.3)
4 15 (25.4) 18 (30.5) 33 (28.0)
5 1 (1.7) 1 (1.7) 2 (1.7)
Alcohol consumption, no. (%) 0.387
None 47 (80.7) 43 (72.9) 90 (76.3)
Present 12 (20.3) 16 (27.1) 28 (23.7)
Underlying disease, no. (%)
Hypertension 52 (88.1) 54 (91.5) 106 (89.8) 0.542
Diabetes mellitus 24 (40.7) 18 (30.5) 42 (35.6) 0.249
Ischemic heart disease 3 (5.1) 1 (1.7) 4 (3.4) 0.618
Stroke 4 (6.8) 2 (3.4) 6 (5.0) 0.579
Previous statin use, no. (%) 9 (15.2) 9 (15.2) 18 (15.2) 1.000
Medication, no. (%)
Aspirin 20 (33.9) 16 (27.1) 36 (30.5) 0.424
ACEi/ARB 52 (88.1) 52 (88.1) 104 (88.1) 1.000
β-Blocker 18 (30.5) 15 (25.4) 33 (28.0) 0.538
Calcium channel blocker 33 (59.9) 24 (40.7) 57 (48.3) 0.097
Loop diuretics 10 (16.9) 9 (15.3) 19 (16.1) 0.802
Thiazide 10 (16.9) 6 (10.1) 16 (13.5) 0.282
Baseline laboratory tests, mg/dL, mean (SD)
Total cholesterol 228.7 (36.8) 220.0 (36.4) 224.4 (36.8) 0.199
LDL-C 143.9 (28.1) 137.0 (28.4) 140.5 (28.3) 0.186
HDL-C 46.9 (14.5) 48.8 (13.5) 47.8 (14.0) 0.464
Triglycerides 190.3 (73.0) 167.6 (70.7) 178.9 (72.5) 0.090
Creatinine 2.0 (0.9) 2.0 (0.8) 2.0 (0.8) 0.816
ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; CKD ¼ chronic kidney disease.
Clinical Therapeuticsblood levels of LDL-C, TC, and TG. Levels of HDL-C
signiﬁcantly increased in both groups. A between-
group analysis of HDL-C level after treatment re-
vealed a signiﬁcantly higher HDL-C level in the test
group than in the control group (P ¼ 0.012). There
were no between-group differences in LDL-C, TC, or
TG level after treatment (Table II).
Patient LDL-C levels decreased by 35.1% (SD
15.7%) in the test group and by 35.6% (SD 14.6%)
in the control group (P ¼ 0.858). The 95% CI of the1186difference in the percentage of change in LDL-C level
between the test and control groups was (–6.0% to
5.0%), which did not meet the predeﬁned noninferiority
margin (–6.5%) in a 1-tailed signiﬁcance test (Figure 2).
Adverse Events
One patient in the test group discontinued the study
because of a side effect (dizziness) of the test drug. The
medication was well tolerated by all other participants.
The number and incidence of total adverse events wereVolume 36 Number 8
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Figure 2. Percentage of change in lipid para-
meters after treatment. TC ¼ total
cholesterol; TG ¼ triglycerides.
Y.J. Yi et al.similar in both groups. In terms of a causal relation-
ship, the adverse events were classiﬁed into 5 catego-
ries: deﬁnitely related, probably related, possibly
related, uncertainly related, and not related to treat-
ment. Each category was further deﬁned according toTable II. Profiles and differences of fasting lipids at bas
Test Group (n ¼ 59)
Baseline
8 Weeks After
Treatment
P (Within
Group)
Total cholesterol,
mg/dL
228.7 (36.8) 172.3 (35.1) o0.001
Change, %* −24.3 (12.5) o0.001
Triglycerides,
mg/dL
190.3 (73.0) 159.8 (65.9) o0.001
Change, %* −10.6 (35.1) 0.023
LDL-C, mg/dL 143.9 (28.1) 92.8 (25.7) o0.001
Change, %* −35.1 (15.7) o0.001
HDL-C, mg/dL 46.9 (14.5) 51.0 (15.6) 0.001
Change, %* 10.2 (20.7) o0.001
Values shown are mean (SD).
*Percentage of change from baseline to end of treatment phase
August 2014the chronological order of administration, a response
of discontinuation or redosing, and other signiﬁcant
causes of the adverse events.
Treatment-related adverse events are shown in Table
III. In total, 10 patients in the test group and 8 in the
control group reported treatment-related adverse events.
In 1 patient in the control group both edema and
nausea developed during the trial. There was no differ-
ence between the 2 groups in the incidence of treatment-
related adverse events (P ¼ 0.691, by the χ2 test).
DISCUSSION
The present study was designed as a double-blind,
prospective, randomized clinical trial with an active
comparator. It compared the efﬁcacy and safety
proﬁle of morning administration of a CR simvastatin
formulation with those of IR simvastatin in patients
with underlying CKD. The difference in the percent-
age of change in LDL-C level did not meet the
predeﬁned noninferiority margin. This ﬁnding sug-
gests that CR simvastatin has an efﬁcacy similar to
that of IR simvastatin. In the Scandinavian Simvasta-
tin Survival Study (4S),2 simvastatin doses of 20 to 40
mg/d lowered the LDL-C level by 35%, which was
similar to results seen in the present study of IR
simvastatin efﬁcacy. There were also no signiﬁcant
differences in the incidence of treatment-related ad-
verse events.eline and 8 weeks after treatment.
Control Group (n ¼ 59)
P (Between
Groups After
Treatment)Baseline
8 Weeks After
Treatment
P (Within
Group)
220.0 (36.4) 160.6 (31.9) o0.001 0.587
−26.5 (12.0) o0.001 0.317
167.6 (70.7) 136.6 (61.6) o0.001 0.963
−12.4 (33.2) 0.001 0.575
137.0 (28.4) 87.5 (23.2) o0.001 0.722
−35.6 (14.6) o0.001 0.858
48.8 (13.5) 50.7 (14.3) 0.011 0.012
4.5 (11.4) 0.003 0.064
.
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Table III. Treatment-related adverse events among the study participants.
Test Group
(n ¼ 62*)
Control Group
(n ¼ 59)
Total
(N ¼ 121*) P
Gastrointestinal disorders
Nausea 2 (3.2) 2 (3.4) 4 (3.3)
Abdominal pain 0 (0) 3 (5.1) 3 (2.5)
Diarrhea 1 (1.6) 0 (0) 1 (0.8)
Musculoskeletal disorders
Myalgia 1 (1.6) 2 (3.4) 3 (2.5)
Central nervous system disorders
Headache 2 (3.2) 0 (0) 2 (1.7)
Dizziness 1 (1.6) 0 (0) 1 (0.8)
Urinary system disorders
Albuminuria 2 (3.2) 0 (0) 2 (1.7)
Other disorders
Edema 1 (1.6) 1 (1.7) 2 (1.7)
Total events 10 (16.1) 8 (13.6)† 18 (14.9)† 0.691
Values shown are number (%).
*Three patients who took the test drug at least once but did not undergo efﬁcacy laboratory tests were also included in the
safety analysis.
†One patient in the control group experienced both edema and nausea during medication.
Clinical TherapeuticsWith regard to the secondary end points, the HDL-
C level after treatment was higher in the test group
than in the control group. However, the increment of
HDL-C after treatment was only marginally greater in
the test group. It remains to be investigated in a future
study whether slow controlled release of simvastatin is
more beneﬁcial in terms of HDL-C than its immediate
release.
Dyslipidemia is one of the most important manage-
ment issues for patients with CKD. It is known that an
abnormality of plasma lipoprotein metabolism in
kidney disease causes dyslipidemia,21,22 and it is also
suggested that lipid toxicity causes glomerular and
tubulointerstitial injury, thereby generating a vicious
cycle.23,24 A meta-analysis of randomized, controlled
trials reported that lipid lowering preserved the
glomerular ﬁltration rate and reduced proteinuria in
patients with renal disease.25
Although 2 large-scale clinical trials in patients
with CKD have reported conﬂicting results for the
effects of statin therapy on cardiovascular outcomes
and all-cause mortality,26,27 1 recent meta-analysis
reported that statin therapy reduces the risk of major1188cardiovascular events in patients with CKD.8 Such
evidence suggests that statin treatment could be
justiﬁed for predialysis in patients with CKD.
Simvastatin is an established HMG-CoA reductase
inhibitor that has been studied in 2 large-scale out-
come trials, the Heart Protection Study and the 4S.2,13
These 2 landmark studies showed that simvastatin
treatment reduced coronary heart disease and all-
cause mortality as their primary outcome, and con-
ﬁrmed the long-term safety proﬁle.
The half-life of the active metabolite of conven-
tional IR simvastatin is 1.9 hours.28 A few studies on
the administration time of IR simvastatin have
reported that lowering of serum LDL-C levels is more
pronounced with evening versus morning administra-
tion.14,29,30 According to these results, it is recom-
mended to take IR simvastatin in the evening.31
However, given that CKD patients are likely to take
multiple medications such as aspirin, antihypertensive
drugs, diuretics, and phosphate binders, evening
administration could render the medication sche-
dule more complex and might compromise patient
compliance.10,11 The present study showed that theVolume 36 Number 8
Y.J. Yi et al.therapeutic efﬁcacy of morning administration of CR
simvastatin is equivalent to that of evening adminis-
tration of IR simvastatin in terms of lowering LDL-C,
TC, and TG levels. Therefore, morning administration
of CR simvastatin could simplify the dosing schedule
and improve the compliance of patients with CKD
who are taking multiple medications.
According to a previous study,32 common adverse
effects of simvastatin include gastrointestinal symptoms
such as constipation, abdominal pain, and ﬂatulence. In
the present study, there was no difference in the
frequency of gastrointestinal side effects between the
test and control groups. Myopathy is a common
adverse effect of HMG-CoA reductase inhibitors. The
deﬁnition of myopathy in the literature is broad,
ranging from mild muscular pain to severe rhabdo-
myolysis. In a previous study,32 myopathy leading to
the discontinuation of simvastatin developed in 0.08%
of patients. It is also known that the frequency of severe
biochemical abnormalities (serum creatine kinase level
410 times the upper normal level) is very low.33 In this
study, overall, there were 3 cases of myalgia (2.5%)
related to statin administration, and no difference was
reported in the frequency of myalgia between the 2
groups. Only 1 patient (0.8%) in the test group
exhibited an increase in creatine kinase 410 times the
upper limit of normal at the end of treatment, which
returned to a normal level after completing treatment.
The present study has the following limitations: (1)
The ITT population was smaller than we expected.
This was due to a higher dropout rate and several
patients who failed to undergo the efﬁcacy test at the
end of treatment. (2) Dietary compliance of both
groups was assumed to be equivalent because both
groups were equally given TLC during the screening
and follow-up periods.
CONCLUSIONS
For patients with CKD, morning administration of CR
simvastatin and evening administration of IR simvas-
tatin didn't show statistically signiﬁcant differences in
safety proﬁle or efﬁcacy. Morning administration of
CR simvastatin may simplify the administration sched-
ule and improve the compliance of patients with CKD
who are taking multiple medications.
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